Tetra Bio-Pharma announced that the company’s investigational new drug involving cannabinoids, QIXLEEF, received guidance to strengthen its nonclinical and toxicological data from the U.S. Food and Drug Administration, which brings the aerosol botanical therapy closer to marketing approval.
The U.S. health regulator on January 13 approved Zoetis Inc,’s once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats.
Drugmaker Biohaven Pharmaceutical said on December 6 the company’s intranasal spray to treat migraine showed rapid pain relief and met the main goals in a late-stage study.
BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.
Concentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain.
EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.
STOCKHOLM–(BUSINESS WIRE)–Aerocrine (STO:AEROB) As previously announced, today is the last day of trading in the Aerocrine stock on Nasdaq Stockholm. Following completion of the recent public tender offer, Circassia Pharmaceuticals […]
DUBLIN, IRELAND–(Marketwired – Jul 6, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines […]
Designed to prevent users from overdosing, abuse-deterrent opioids aim to diminish the effects of today’s epidemic by limiting the ways addicts can alter prescription painkillers for their needs. These drugs, subject […]